Research programme: anticancer therapeutics - IUCT/JPT Peptide Technologies/LEITAT Technological Center
Alternative Names: Biofocused anticancer therapies - IUCT/JPT Peptide Technologies/LEITAT Technological Center; Peptidomimetic-linked nucleoside analogues - IUCT/JPT Peptide Technologies/LEITAT Technological CenterLatest Information Update: 16 Jul 2016
At a glance
- Originator IUCT; JPT Peptide Technologies; LEITAT Technological Center
- Class Nucleosides; Peptidomimetics
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Spain
- 17 Jan 2012 Early research in Cancer in Germany (unspecified route)